GFM
ESPR

GF Fund Management’s Esperion Therapeutics ESPR Stock Holding History

GF Fund Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Sell
5,061
-284
-5% -$794 ﹤0.01% 501
2026
Q1 		$14.6K Buy
5,345
+649
+14% +$2.06K ﹤0.01% 528
2025
Q4 		$17.4K Buy
4,696
+358
+8% +$1.16K ﹤0.01% 524
2025
Q3 		$11.5K Sell
4,338
-707
-14% -$1.37K ﹤0.01% 543
2025
Q2 		$4.97K Hold
5,045
– – ﹤0.01% 626
2025
Q1 		$7.26K Buy
5,045
+908
+22% +$1.67K ﹤0.01% 600
2024
Q4 		$9.1K Buy
+4,137
New +$9.65K ﹤0.01% 559

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

GF Fund Management's ESPR Position: Q2 2026 in Review

GF Fund Management reduced its Esperion Therapeutics (ESPR) stake by 5.3% in Q2 2026, selling an estimated $794 and leaving 5,061 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #501.

GF Fund Management first reported a position in ESPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $17.4K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • GF Fund Management held 5,061 shares of Esperion Therapeutics worth $16K as of Q2 2026.
  • GF Fund Management sold 284 Esperion Therapeutics shares in Q2 2026, an estimated $794.
  • Esperion Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #501 holding.
  • GF Fund Management first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Esperion Therapeutics position peaked at $17.4K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.